 SOUTH SAN FRANCISCO, Calif., May 20, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today announced that management plans to participate in five upcoming virtual investor conferences. 